peptide mapping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-13. Numbers and descriptions here follow the published literature rather than marketing material.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic peptide | Melanocortin receptor agonist family |
| Molecular weight | Approximately 1025 Da | Free base form |
| Appearance | White to off-white powder | Lyophilized product |
| Solubility | Soluble in water | Also dissolves in polar organic solvents |
| Storage temperature | -20 degrees Celsius | Dry and protected from light |
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
=== Gastrointestinal tract === In the gastrointestinal tract, KOR is expressed on myenteric and submucosal plexus neurons, where they modulate intestinal motility and secretion. Both KOR and MOR mRNAs are expressed in all investigated gastrointestinal regions in one study, with the stomach and proximal colon displaying the highest expression levels, and the duodenum exhibiting the lowest. KOR in the proximal colon represented 40% of the amount found in the brain. A higher number of neurons expressing KOR-like immunoreactivity are visualized in the myenteric plexus with a smaller number in the submucosal plexus, unlike the distribution pattern of MORs.
== Research == Blisibimod, an inhibitor of both soluble and membrane-bound BAFF, has demonstrated similar reductions of B cells in clinical trials and is being investigated in a Phase II clinical study for patients with lupus. BR3-Fc, a recombinant fusion protein built with the extracellular ligand-binding portion of BAFF-R, blocks activation of this receptor by BLyS and is in early-stage pharmaceutical development. Rituximab, an anti-CD20 monoclonal antibody, has been approved for some indications. Ocrelizumab, ofatumumab, and "third-generation" anti-CD20 monoclonals are in development. Other drugs addressing B lymphocyte hyperactivity include atacicept, a recombinant fusion protein that is built with the extracellular ligand binding portion of TACI and blocks activation of TACI by APRIL and BLyS. It failed a Phase II trial for multiple sclerosis.
If the player rescues all of the Little Sisters, Jack takes them back to the surface with him and adopts five as his daughters. Tenenbaum happily narrates how they go on to live full lives under his care, eventually surrounding him on his deathbed. If the player harvests any of the Little Sisters, Jack turns on the Little Sisters to harvest their ADAM. Tenenbaum condemns Jack as he leads a group of Splicers to take over a nuclear warhead-armed submarine. Depending on how many of the Little Sisters are harvested, Tenenbaum's narrative changes from sad and mournful to angry and harsh.
=== Endothelial colony forming cell === Endothelial colony forming cells are a late outgrowth cell type; that is, they are only isolated after significantly longer culture than CFU-Hill cells. ECFCs are isolated by plating peripheral blood mononuclear fraction on collagen-coated plates, removing non-adherent cells, and culturing for weeks until the emergence of colonies with a distinctive cobblestone morphology. These cells are phenotypically similar to endothelial cells and have been shown to create vessel-like structures in vitro and in vivo. In 2019, David Smadja described a standardized protocol for the isolation and culture of endothelial colony-forming cells (ECFCs) in humans. This was followed in 2023 by a publication surveying laboratory practices among teams working with these cells, conducted under the auspices of the International Society on Thrombosis and Haemostasis Vascular Biology Scientific Subcommittee. In 2025, a review emphasized the unique vasculogenic and immunomodulatory properties of cord blood-derived ECFCs (CB-ECFCs), highlighting their high proliferative capacity, immune-privileged status, and therapeutic potential in vascular regeneration and tissue engineering.
==== Iodine crystals ==== A potentially lower cost alternative to using iodine-based water purification tablets is the use of iodine crystals, although there are serious risks of acute iodine toxicity if preparation and dilution are not measured with some accuracy. This method may not be adequate in killing Giardia cysts in cold water. An advantage of using iodine crystals is that only a small amount of iodine is dissolved from the iodine crystals at each use, giving this method of treating water a capability for treating very large volumes of water. Unlike tetraglycine hydroperiodide tablets, iodine crystals have an unlimited shelf life as long as they are not exposed to air for long periods of time or are kept under water. Iodine crystals will sublimate if exposed to air for long periods of time. The large quantity of water that can be purified with iodine crystals at low cost makes this technique especially cost effective for point of use or emergency water purification methods intended for use longer than the shelf life of tetraglycine hydroperiodide.
Sources: en.wikipedia.org
There are no definite historical records concerning the particular shroud currently at Turin Cathedral prior to the 14th century. A burial cloth, which some historians maintain was the Shroud, was owned by the Byzantine emperors but disappeared during the Sack of Constantinople in 1204. Although there are numerous reports of Jesus's burial shroud, or an image of his head, of unknown origin, being venerated in various locations before the 14th century, there is no historical evidence that these refer to the shroud currently in Turin. In 1353 the village of Lirey, in north-central France, was enriched with a small collegiate church endowed by the local feudal lord, a knight named Geoffroi de Charny. Charny died in 1356 at the Battle of Poitiers. Around 1355, the dean of the chapter of Lirey, Robert de Caillac, began exhibiting in the church a long fabric that bore an image of the mangled body of Jesus. Nicole Oresme, the Bishop of Lisieux, denounced the shroud as a forgery, believing it to be the work of clergymen for the purpose of making money for their churches. In 1390 the Bishop of Troyes, Pierre d'Arcis, who had jurisdiction over the church in Lirey, wrote a lengthy memorandum to Antipope Clement VII (recognized as Pope by the Church in France during the Western Schism), declaring that the Shroud was a forgery and that a previous Bishop of Troyes, Henri de Poitiers, had identified the artist who had made it.
=== Hiroshima === Extreme examples of the ginkgo's tenacity may be seen in Hiroshima, Japan, where six trees growing between 1 and 2 kilometres (1⁄2 and 1+1⁄4 miles) from the 1945 atom bomb explosion were among the few living organisms in the area to survive the blast. Although almost all other plants (and animals) in the area were killed, the ginkgos, though charred, survived and were soon healthy again, among other hibakujumoku (trees that survived the blast). The six trees are still alive. They are marked with signs at Housenbou (報専坊) temple (planted in 1850), Shukkei-en (planted about 1740), Jōsei-ji (planted 1900), at the former site of Senda Elementary School near Miyukibashi, at the Myōjōin temple, and an Edo period-cutting at Anraku-ji temple.
=== Brown adipose tissue === Brown adipose tissue stores free fatty acids rather than triglycerides, and is especially abundant in newborn and hibernating mammals. Brown adipose tissue is involved in thermogenesis, and has a considerably higher glyceroneogenesis activity. Brown adipose tissue contains more glyceroneogenesis-related enzymes, in particular PEPC-K and glycerol kinase. PEPC-K is around 10 times more active than in white adipose tissue, and is the key regulatory enzyme that controls the activity of the pathway. Glycerol kinase phosphorylates glycerol to generate glycerol 3-phosphate, which is used to build triglycerides. An increase in the activity of glycerol kinase will increase the production of glycerol 3-phosphate. Glyceroneogenesis in brown adipose tissue contributes to thermogenesis, a process that generates heat in warm-blooded animals by delivering free fatty acids to the mitochondria. In normal conditions, thermogenesis is down-regulated by the low concentration of free fatty acids in the cytosol, because glyceroneogenesis re-esterifies fatty acids to triglycerides. When exposed to cold, a neurotransmitter hormone called norepinephrine suppresses the activity of PEPC-K and thus the glyceroneogenesis re-esterification, increasing the availability of free fatty acids within the cell. Excess free fatty acids in the cytosol will consequently be delivered to the mitochondria for thermogenesis.
The Huk movement was mainly spread in the central provinces of Nueva Ecija, Pampanga, Tarlac, Bulacan, and in Nueva Vizcaya, Pangasinan, Laguna, Bataan, and Quezon. An important movement in the campaign against the Huks was the deployment of hunter-killer counter guerrilla special units. The "Nenita" unit (1946–1949) was the first of such special forces whose main mission was to eliminate the Huks. The Nenita force was commanded by Major Napoleon Valeriano. The Nenita terror tactics which were not only committed against dissidents but also towards law-abiding people sometimes helped the Huks gain supporters as a consequence. In July 1950, Major Valeriano assumed command of the elite 7th Battalion Combat Team (BCT) in Bulacan. The 7th BCT would develop a reputation toward employing a more comprehensive, more unconventional counterinsurgency strategy and reduced the random brutality against the civilian population.
GSHS (disambiguation) ГШ (disambiguation) (Russian: GSh) All pages with titles containing GSH or GSHs All pages with titles containing g-s-h All pages with titles beginning with GSH All pages with titles beginning with Gsh All pages with titles beginning with G.S.H. GS (disambiguation)
Sources: en.wikipedia.org
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.
It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.
Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.